Markets

Navidea Biopharmaceuticals Inc. Enters Oversold Territory - Tale of the Tape

A generic image of a pen on a chart
Credit: Shutterstock photo

Navidea Biopharmaceuticals Inc.'s ( NAVB ) share price has entered into oversold territory with an RSI value of 23.98. The Zacks Consensus Estimate on Navidea Biopharmaceuticals Inc.'s earnings for the full year period has profit by 0.00 cents over the past two months to $-0.30 per share. Currently, Navidea Biopharmaceuticals Inc. is a Zacks #2 Rank ("Buy"), suggesting that now might be a good time to get in on ( NAVB ) after its recent drop.

NAVIDEA BIOPHAR (NAVB): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NAVB

Other Topics

Investing Stocks

Latest Markets Videos